Acute Kidney Injury (AKI) has long been considered an utterly reversible syndrome. However, recent evidence shows that AKI is a major risk factor for progression to Chronic Kidney Disease (CKD) (Hazard Ratio HR 8.8) and end-stage renal disease (HR 3.1) [
87], especially in ICU patients [
88]; the risk increases with AKI severity. AKI is also associated with cardiovascular risk: congestive heart failure (HR up to 2.2) [
87] and acute coronary event (HR 1.7 after renal replacement therapy-requiring AKI) [
89]; the risk of death or admission for a major adverse cardiac event is higher after AKI than after myocardial infarction [
90]. From those epidemiologic findings emerged the concepts of “maladaptive repair” [
91] and interconnection between AKI and CKD [
92]. The predominant experimental model for progression from AKI to CKD is ischemia/reperfusion (I/R) in rodents. Two main mechanisms of kidney damage emerge from experimental findings, implying different cell death mechanisms: tubular and vascular damage, both leading to interstitial fibrosis. I/R in proximal tubules induces necroptosis, prolonged expression of pro-inflammatory cytokines (IL-18, IL-1ß and TGF-ß), macrophage infiltrate, and inflammasome activation, with an amplification loop, even after kidney function normalization [
93,
94]. Those lesions are responsible for fibrosis and CKD. Mitochondria is a key effector of maladaptive repair. In proximal tubules, ATP dynamic-related protein 1depletion induced by I/R is responsible for mitochondrial fission via Dynamic-Related Protein 1, inducing Reactive Oxygen Species liberation. Therefore, the tubular cell proliferation is inhibited, whereas IL-6 secretion , neutrophils recruitment [
95] and apoptosis are increased. Infusion of a mitoprotective agent 1 month after AKI decreases inflammation, restores structural kidney integrity (capillaries and podocytes), and decreases interstitial fibrosis [
94]. Autophagy in tubular cells, despite a protective effect on initial AKI, is responsible for more inflammation and worse kidney outcome 30 days after I/R in mice [
96], via cell cycle arrest in G2—M phase. It results in up-regulation of profibrotic cytokines (TGF ß, connective tissue growth factor), activation of COL4A1 and COL1A1 genes, and cellular dedifferentiation [
97,
98]. The intensity of fibrosis does not depend on the level of apoptosis (preponderant role of cell cycle arrest over apoptosis on fibrosis process). Epigenetic phenomenon is also involved: histone deacetylase inhibition improves long-term kidney function by reducing fibrosis [
99]. Peritubular capillary density decreases in the weeks following I/R, despite an initial repair of tubular damage [
100]. Thus, sensitivity to angiotensin 2 and hypertension increases. The delayed expression of TGF-ß in ischemic kidney is implied in capillary rarefaction [
100,
101], such as endothelin-1, which transcription is sustainably increased after I/R, resulting in a reduction in kidney mass [
102]. Capillary rarefaction induces chronic hypoxia, persistent up to 5 weeks after I/R, with elevation in HIF 1 (hypoxia-inducible growth factor) [
103]. Basile et al. demonstrated evidence of endothelial–mesenchymal transition, which is much more prevalent than epithelial–mesenchymal transition [
104]. Apoptosis also plays a role in capillary rarefaction: indeed, caspase-3 (the main effector of apoptosis) remains activated several weeks after I/R, and caspase-3
−/− mice show less microvascular rarefaction and renal fibrosis [
103]. In human cell culture, hypoxia enhances apoptosis in endothelial but not epithelial cells, while necrosis is rather a tubular concern [
103]. Finally, mitochondrial fission induced by DRP 1 is also implied in capillary rarefaction [
95].
In conclusion, the physiopathology of progression from AKI to CKD has been well described in the last two decades, opening the field for renoprotective interventional studies: mitoprotection [
94], inhibition of deleterious effectors, such as histone deacetylase [
109], TGF-ß, or endothelin [
101], or administration of renoprotective effectors, such as VEGF or arginine [
100,
104].